Navigation Links
NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
Date:2/27/2008

Primary and Secondary Endpoints Do Not Achieve Statistical Significance

Company Affirms Plans to File NGX-4010 NDA in 2008

Schedules Investor Conference Call at 5:00 p.m. EST

SAN MATEO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced preliminary top-line results from study C119, its second Phase 3 clinical trial of NGX-4010, the Company's dermal patch drug candidate, in patients with HIV-distal sensory polyneuropathy (HIV-DSP). The prespecified analysis of the primary endpoint, comparing all patients treated with NGX-4010 compared to all patients treated with the control patch, did not meet statistical significance (p=0.1), with the overall NGX-4010 treatment group achieving a 29.5% reduction in pain from baseline over weeks 2 to 12 compared to a 24.6% reduction for the control group. The results were confounded by a much higher than anticipated control group response overall and, in particular, in the 60-minute control arm.

Dr. Jeffrey Tobias, Chief Medical Officer, commented, "We observed responses in the NGX-4010 treatment arms consistent with what we have seen in multiple previous studies. However, the response in the 60-minute control group was greater than anticipated. We are encouraged that the safety profile of this study supports the lack of any observed major safety issues associated with NGX-4010 and that treatment with NGX-4010 was well tolerated. Since these results are preliminary, we have more analysis to carry out on this data. However, our initial evaluation of the data suggests that the NGX-4010 treatment arms behaved similarly to our oth
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
4. EndoGastric Solutions(TM) Announces Results of EsophyX(TM) Multi-Center GERD Study
5. Dong-A PharmTech Co., Ltd. Announces Portal Hypertension Clinical Trial With Udenafil
6. MacuSight(TM) Announces Positive Preliminary Results From Phase 1 Study of Sirolimus in Wet Age-Related Macular Degeneration
7. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
8. amfAR Announces Funding for HIV Services and Research Aimed at Men Who Have Sex With Men in Developing Countries
9. ATS Medical Announces Initial Clinical Results of Stand-Alone Atrial Fibrillation Procedures Using ATS CryoMaze Product Line
10. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
11. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 2013  TeamHealth Medical Call Center (THMCC), a ... advice lines, announces its newly formed Clinical Advisory ... administrative leaders, provides clinical expertise to advance THMCC,s ... for hospital clients, physician clients and patients. ... it,s imperative to continuously advance our services and ...
(Date:5/23/2013)... 23, 2013 More than half of women ... from chemotherapy and still have excellent outcomes. To educate ... of the largest sources of online consumer information about ... Facebook page provide recently diagnosed women with information sources, ... chemotherapy. "We anticipate these innovative social media ...
(Date:5/23/2013)... May 23, 2013 Anthem Blue Cross patients ... have required them to obtain their medications by mail ... and Whatley Kallas LLC.  The lawsuit, ... that Blue Cross,s mandatory mail order program announced late ... and privacy. "This settlement brings to a ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3
(Date:5/24/2013)... 2013 The Dictation Source recently added ... clients. As a result of its National marketing efforts, ... 20 states around the nation. , Since 1991, The ... to the healthcare industry . Dictation Source is owned ... years of clinical work experience to provide the solutions ...
(Date:5/24/2013)... -- The number of U.S. patients admitted to ... an emergency room has increased by nearly 50 ... conducted by researchers at the George Washington University ... Washington, D.C., found that patients wait five hours ... admitted to the ICU. The researchers said improved ...
(Date:5/24/2013)... 24, 2013 The SunglassFIX Photo ... sunglasses all while learning how to make their ... Contestants only need to upload pictures of ... "like" The Sunglass Fix on Facebook in order ... the largest lens replacement online store . ...
(Date:5/24/2013)... France: Transcatheter aortic valve implantation (TAVI) is effective and ... on first results from a multicentre Asian registry reported ... has become a treatment option for selected patients with ... all from North American or European centres," Paul Chiam, ... told the conference. He explained that it is unknown ...
(Date:5/24/2013)... In a coup that surely made other ... of the Estetica Institute of the Palm Beaches performed eye ... popular morning show, “The Mo & Sally Morning Show.” The ... satisfaction with the results, giving Dr. DeLange and the team ... Beach Gardens, very valuable free publicity. , Dr. DeLange, the ...
Breaking Medicine News(10 mins):Health News:The Dictation Source Signs Two National Hospital Chains 2Health News:The Dictation Source Signs Two National Hospital Chains 3Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Break the Sunglass Mold – Reuse 'Em, Don’t Toss 'Em then Enter the SunglassFIX Photo Contest to Win 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:Dr. Greg DeLange of the Estetica Institute Recently Performed Eye Surgery on Both Members of Popular Morning Radio Team 2
... New Executive LeadershipKOBE, Japan, March 5 Sysmex ... medical diagnostics instrument manufacturer and laboratory information systems ... Corporate and its subsidiaries in the Americas, Europe ... Obe will return to Sysmex Corporate after a ...
... more than 3,000 women in the U.S. and southern ... a vaginal microbicide gel for preventing HIV infection in ... Retroviruses and Opportunistic Infections (CROI), one 0.5 % dose ... to cells in the genital tract, was 30% effective. ...
... printing superstore was honored for ecommerce expertise when President Michael Del ... version of the highly respected Entrepreneur magazine. , ... ... Del Chiaro for the interview based on his proven success in ...
... To Beaver, Star Jerry MathersJACKSON, Miss., March 5 ... will be stopping in Mississippi the week of March ... to help uninsured and financially-struggling Mississippians access information on ... free. With the unemployment rate in Mississippi (7.8 percent) ...
... Inc. (RPI), a wholly owned subsidiary of Ranbaxy ... received approval from the U.S. Food and Drug ... Hydrochlorothiazide (Quinapril + HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg ... was submitted by Ranbaxy, from its Ohm Laboratories ...
... a penile extender every day for six months were able ... to 32% and their erectile function by up to 36%, ... issue of BJU International . , Researchers from San ... now suggesting that this treatment could provide a viable alternative ...
Cached Medicine News:Health News:Sysmex Corporation Announces Organizational Changes 2Health News:Clinical trial finds microbicide promising as HIV prevention method for women 2Health News:My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 4Health News:Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets 2Health News:Penile extender increased flaccid length by almost a third says independent clinical study 2
... Our slimmest full-featured bronchofiberscope yet. The BF-3C40's ... by 0.2mm from the previous model. It ... Olympus models, thanks to the use of ... enlarge the image size by 70 percent. ...
... designed specifically to enable direct inspection of ... for pediatric applications as well. Its insertion ... 2.8mm across. As a result, insertion into ... greater ease. And since this sophisticated scope ...
Indications For Usage: , Thoracic surgery. , Broncho-spirometry. , Thoracoscopies. , Differential or selective lung ventilation. , Lung Lavage. ...
... double lumen tube made of silicone rubber with ... to the characteristics of silicone rubber, Silbronco is ... insertion. Furthermore, the tube will not soften like ... term surgery., ,Silbronco is also especially useful ...
Medicine Products: